Scholar Rock (SRRK) Q2 FY26 earnings call

Scholar Rock is in a defining period, driving towards the U.S. launch of apitegromab this quarter, with its BLA progressing well through FDA review via two independent fill/finish facility paths. The company is also advancing its European MAA and expanding its anti-myostatin pipeline with new clinical studies in SMA and FSHD, supported by a strong financial position and robust commercial readiness.